Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from…

Read more »

The post Gilead Prices COVID-19 Drug Candidate Remdesivir at $2,340/Patient appeared first on Hamodia.